cis-2-(Aminomethyl)cyclohexanol | 313351-50-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: cis-2-(Aminomethyl)cyclohexanol
• 英文别名: (1R,2R)-2-(aminomethyl)cyclohexanol；cis-2-Aminomethyl-1-cyclohexanol；(1R,2R)-2-(aminomethyl)cyclohexan-1-ol
• CAS: 313351-50-7
• 化学式: C₇H₁₅NO
• 分子量: 129.202
• InChiKey: JGKFBZBVCAWDFD-RNFRBKRXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  cis-2-(Aminomethyl)cyclohexanol 、 水杨醛 生成
  参考文献：
  名称：

  FULOP, FERENC;LAZAR, LASZLO;GABOR, BERNATH;ISTVAN, PELCZER, MAGY KEM. FOLYOIRAT. , 95,(1989) N, C. 212-215

  摘要：

  DOI：
• 作为产物：
  描述：

  (4aR,8aR)-2-phenyl-4a,5,6,7,8,8a-hexahydro-4H-1,3-benzoxazine;hydrochloride 、 水 生成 cis-2-(Aminomethyl)cyclohexanol
  参考文献：
  名称：

  YAKUSHEVA A. D.; XASIRDZHEV A. B.; BOJKO I. P.; MALINA YU. F.; DANILOVA O+, MOSK. IN-T TONK. XIM. TEXNOL. M., 1979, 14 S., IL., BIBLIOGR. 6 NAZV. (RU+

  摘要：

  DOI：

文献信息

• Novel aminotriazolone compounds, method for preparing same and pharmaceutical compositions containing same
  申请人：——

  公开号：US20040029875A1

  公开（公告）日：2004-02-12

  A compound of formula (I): 1 wherein: R 1 and R 2 represent hydrogen or a group as defined in the description, R 3 represents hydrogen or alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl, R 4 represents a group of formula (II): 2 wherein W and B are as defined in the description, R 5 represents hydrogen or alkyl, A represents a group selected from -A 2 -, -A 1 -A 2 -, -A 2 -A 1 - and -A 1 -A 2 -A 1 -, V is as defined in the description.

  一种化合物的化学式（I）： 其中： R1和R2代表氢或描述中定义的基团， R3代表氢或烷基，烯基，炔基，芳基，杂芳基，环烷基或杂环烷基， R4代表化学式（II）的基团： 其中W和B如描述中定义， R5代表氢或烷基， A代表从-A2-，-A1-A2-，-A2-A1-和-A1-A2-A1-中选择的基团， V如描述中定义。
• NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES
  申请人：Merck Patent GmbH

  公开号：US20160168090A1

  公开（公告）日：2016-06-16

  The present invention relates to indole compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.

  本发明涉及吲哚化合物及其药用可接受的组合物，用作P2X7拮抗剂，用于治疗与P2X7相关的疾病。
• SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3
  申请人：YAO Wenqing

  公开号：US20120165305A1

  公开（公告）日：2012-06-28

  The present invention relates to substituted imidazopyridazines and substituted benzimidazoles, as well as pharmaceutical compositions comprising the same, which are FGFR3 inhibitors useful in the treatment of cancer and other diseases.

  本发明涉及替代咪唑吡啶和替代苯并咪唑，以及包含它们的药物组合物，这些是FGFR3抑制剂，可用于治疗癌症和其他疾病。
• TRPV3 Modulators
  申请人：Clapham Bruce

  公开号：US20120245124A1

  公开（公告）日：2012-09-27

  Disclosed herein are modulators of TRPV3 of formula (I) wherein X 1 , X 2 , R 1 , R 2 , R x , and n are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

  本文披露了具有如下式（I）的TRPV3调节剂，其中X1、X2、R1、R2、Rx和n如规范中定义。还提供了包含这种化合物的组合物以及使用这种化合物和组合物治疗疾病和疾病的方法。
• Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities
  作者：Susanne Berglund、Bryan J. Egner、Henrik Gradén、Joakim Gradén、David G.A. Morgan、Tord Inghardt、Fabrizio Giordanetto

  DOI：10.1016/j.bmcl.2009.05.066

  日期：2009.8

  The discovery and optimization of piperidin-4-yl-urea derivatives as MCH-R1 antagonists is herein described. Previous work around the piperidin-4-yl-amides led to the discovery of potent MCH-R1 antagonists. However, high affinity towards the hERG potassium channel proved to be an issue. Different strategies to increase hERG selectivity were implemented and resulted in the identification of piperidin-4-yl-urea

  本文描述了作为MCH-R1拮抗剂的哌啶-4-基-脲衍生物的发现和优化。以前关于哌啶丁-4-基-酰胺的研究导致发现了有效的MCH-R1拮抗剂。然而，对hERG钾通道的高亲和力被证明是一个问题。实施了提高hERG选择性的不同策略，并导致鉴定出哌啶-4-基-脲化合物为有效的MCH-R1拮抗剂，且对hERG的抑制作用最小。